![]()  | |
| Names | |
|---|---|
| Preferred IUPAC name
 4-{4-(4-Fluorophenyl)-2-[4-(methanesulfinyl)phenyl]-1H-imidazol-5-yl}pyridine  | |
| Other names
 RWJ-64809;  | |
| Identifiers | |
3D model (JSmol)  | 
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.214.849 | 
| EC Number | 
  | 
PubChem CID  | 
|
| UNII | |
CompTox Dashboard (EPA)  | 
|
  | |
  | |
| Properties | |
| C21H16FN3OS | |
| Molar mass | 377.43 g/mol | 
| Appearance | White to off-white solid | 
| Solubility in DMSO | 50 mg/mL | 
| Hazards | |
| GHS labelling: | |
![]() ![]()  | |
| Danger | |
| H302, H318 | |
| P264, P270, P280, P301+P312, P305+P351+P338, P310, P330, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). 
Infobox references  | |
SB 203580 is a specific inhibitor of p38α and p38β which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27. At low concentrations, it does not inhibit JNK activity. SB-203580 was recently assigned the INN Adezamapimod, and is currently in phase 2 clinical trials to prevent post-operative tissue adhesion.
References
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.


